# Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Study · id `cardio:ct-nct03418233` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03418233](<https://clinicaltrials.gov/study/NCT03418233>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03418233

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 115 participants.

## Technical summary

Registry record NCT03418233. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-19 (actual); primary completion 2021-01-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 115 participants (enrolled count; ClinicalTrials.gov record NCT03418233, source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)
- Started: 2018-04-19 (actual) (ClinicalTrials.gov record NCT03418233, source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)
- Primary completion: 2021-01-27 (actual) (ClinicalTrials.gov record NCT03418233, source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)
- Completion: 2021-03-31 (actual) (ClinicalTrials.gov record NCT03418233, source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT03418233, source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03418233-2021-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)
- Condition: Heart Failure
- Intervention (Drug): CardioCell
- Intervention (Drug): Placebos
- Lead sponsor: John Paul II Hospital, Krakow
- Lead sponsor class: OTHER
- Collaborator: KCRI
- Collaborator class: OTHER
- Collaborator: National Center for Research and Development, Poland
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: John Paul II Hospital, Krakow (`cardio:org-john-paul-ii-hospital-krakow`)
- Registry lists this organization as a collaborator: National Center for Research and Development, Poland (`cardio:org-national-center-for-research-and-development-poland`)

## Provenance

Content hash: 4bbd02f38e6dd0dcad4c04f9db6022521995803f549a6d0c483844824d33a253
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
